{"id":113474,"date":"2026-09-17T08:03:08","date_gmt":"2026-09-17T08:03:08","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/"},"modified":"2026-09-17T08:03:08","modified_gmt":"2026-09-17T08:03:08","slug":"1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/","title":{"rendered":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019"},"content":{"rendered":"<ul>\n<li style=\"margin-top:0cm;margin-bottom:8pt;text-align:justify\"><em><strong><b><i>Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investment<\/i><\/b><\/strong><\/em><\/li>\n<li style=\"margin-top:0cm;margin-bottom:8pt;text-align:justify\"><em><strong><b><i>Collaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson&#8217;s treatment<\/i><\/b><\/strong><\/em><\/li>\n<\/ul>\n<p align=\"justify\"><b>YONGIN, South Korea, September 17, 2026<\/b> \u2014 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w0yoZEA--om-GXyytUfivoT5lwUuINPZucMrJxtFsftqFT2irIqENK17ZjZfSXGNqe1h5ZpMoWx4LPzeDlyHFPH6IHQmHjFs4_luCPJyOuU=\" rel=\"nofollow\" target=\"_blank\" title=\"1ST Biotherapeutics, Inc.\">1ST Biotherapeutics, Inc.<\/a> (\u201c1STBIO\u201d) and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Omo_UzOGdlG0aXNGebR-v3Jioc2SUZpYyzta0hWO5lbEOabk6zJdT1sbtonEA5gHWNOHaogFsRw84yMTW3RAZstQT38QmJtDLvSQ-egjDbIr3yQJLv9bBHdjJfxJxHaJ\" rel=\"nofollow\" target=\"_blank\" title=\"SK Biopharmaceuticals Co., Ltd.\">SK Biopharmaceuticals Co., Ltd. <\/a>(\u201cSKBP\u201d) today announced that they have entered into an exclusive global licensing agreement and strategic equity investment (SI) partnership to advance 1ST-104, a novel drug candidate for the treatment of Parkinson&#8217;s disease.<\/p>\n<p align=\"justify\">Under the terms of the agreement, 1STBIO will receive an upfront payment of $1.8 million. The total licensing agreement is valued at up to $314.8 million, including a short-term milestone of $1.8 million upon candidate selection and additional milestones. Upon commercialization, 1STBIO is also eligible to receive tiered royalties based on global net sales. Separately, SKBP has made a $2.2 million strategic equity investment in 1STBIO to foster a long-term partnership.<\/p>\n<p align=\"justify\">The licensed program, 1ST-104, is being developed as an oral small-molecule treatment for Parkinson&#8217;s disease, using a dual-inhibition strategy that simultaneously inhibits LRRK2 and c-Abl. LRRK2 is considered a therapeutic target directly linked to the pathogenesis of Parkinson&#8217;s disease. However, some Type 1 LRRK2 inhibitors have faced development challenges, particularly due to pulmonary findings reported in preclinical studies.<\/p>\n<p align=\"justify\">To address these limitations, 1STBIO developed 1ST-104 as a next-generation Type 2 LRRK2 inhibitor. By leveraging a Type 2 binding mode, 1ST-104 offers a differentiated approach compared to conventional Type 1 inhibitors and has demonstrated target selectivity along with blood-brain barrier (BBB) permeability in preclinical studies. Furthermore, since 2024, 1STBIO has been a member of LITE (LRRK2 Investigative Therapeutics Exchange), the research consortium supported by The Michael J. Fox Foundation for Parkinson&#8217;s Research (MJFF)\u2014the world\u2019s leading non-profit funder of Parkinson\u2019s disease research. Through LITE, the company continues to engage in global scientific and technical collaboration.<\/p>\n<p align=\"justify\">&#8220;This agreement serves as a strong validation of 1ST Biotherapeutics&#8217; proprietary discovery capabilities in next-generation target identification and lead optimization,&#8221; said Jamie Jae Eun Kim, CEO of 1ST Biotherapeutics. &#8220;It marks a major milestone by uniting our early-stage R&amp;D strength with SK Biopharmaceuticals&#8217; proven global development and commercial expertise. Through close collaboration with SK Biopharmaceuticals, we will leverage the strengths of both companies to advance the subsequent development of 1ST-104.&#8221;<\/p>\n<p align=\"justify\">Donghoon Lee, CEO of SK Biopharmaceuticals, said, &#8220;This collaboration is significant in that it combines 1ST Biotherapeutics&#8217; early-stage discovery capabilities with SK Biopharmaceuticals&#8217; clinical development and commercialization expertise.&#8221; He added, &#8220;We will work to translate this candidate into successful clinical development, opening up new possibilities for the treatment of Parkinson&#8217;s disease.&#8221;<\/p>\n<p align=\"justify\">###<\/p>\n<p align=\"justify\"><b>About 1ST Biotherapeutics, Inc.<\/b><\/p>\n<p align=\"justify\">Founded in 2016, 1ST Biotherapeutics is a science-driven biopharmaceutical company developing therapies for neurodegenerative diseases, immuno-oncology, and rare diseases. The Company\u2019s immuno-oncology candidate FB849 is currently being evaluated in a Phase 1\/2 clinical trial following the dosing of the first patient in the U.S. in 2023, with clinical development also underway in Korea. For its combination clinical trials, MSD has agreed to provide KEYTRUDA\u00ae (pembrolizumab) at no cost. FB-101, a c-Abl inhibitor being developed for Parkinson\u2019s disease, has completed a Phase 1 single ascending dose (SAD) study in the U.S.<\/p>\n<p align=\"justify\">For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3V87LbXkls9-3Qiu1bslm4hNfM7X2nrnpyp7xZDblv-ho1_wbaaTUIG99oCE9X_ptU3mpyVdNrSyh2HJra3IC7K5mb_NR-7Fbpz9RU3EU2w=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.1stbio.com<\/a>.<\/p>\n<p align=\"justify\"><b>About SK Biopharmaceuticals Co., Ltd.<\/b><\/p>\n<p align=\"justify\">SK Biopharmaceuticals Co., Ltd., together with its U.S. subsidiary SK Life Science, Inc., is a global biopharmaceutical company focused on the discovery, development, and commercialization of treatments for central nervous system disorders. The company independently developed and commercialized XCOPRI\u00ae (cenobamate tablets) for the treatment of partial-onset seizures in adults, and continues to build a global pipeline spanning CNS disorders and oncology. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3V87LbXkls9-3Qiu1bslm7x0xz3f0OBkB68hcL8614Shx6XW4MUHvHITboo2XfjLvVQw3W0ov7jKUqgEuwexUKu95aZ83DdJIf5RXw6uJJcjJY0MBY7ytDZxK3lKoMwmgYKvO0aT8H9x_CgpGtHONTjXve6zDTeiWnsl31fxRFubUTA9oBNu6gyV9aw6fGYn9LWQH9Gqq9F--oqLQoIHptxOo1aUAxEg_zV7xeesKSSSLto0N0sDlUmznxvLYxcKPB8n6dNFU7ubFHq3uX9uGw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.skbp.com\/eng.do<\/a>.<\/p>\n<p align=\"justify\"><b>International Media Inquiries<\/b><\/p>\n<p align=\"justify\">akampion<br \/>Ines-Regina Buth<br \/>Managing Partner<br \/>info@akampion.com<br \/>Tel. +49 30 23 63 27 68<\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investment Collaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson&#8217;s treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":113475,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/media\/NWI2M2NmODEtNWNjYy00MjBkLWI3M2MtNTk0ZWIwNTVlMzIxLTEwMzc0NTQtMjAyNi0wOS0xNy1lbg==\/tiny\/AKAMPION.png","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-113474","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson&#039;s treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Gias Ul Hassan\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan - Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019\" \/>\n\t\t<meta property=\"og:description\" content=\"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson&#039;s treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-09-17T08:03:08+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-09-17T08:03:08+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson&#039;s treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#blogposting\",\"name\":\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \\u20181ST-104\\u2019\",\"headline\":\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \\u20181ST-104\\u2019\",\"author\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml-eu.globenewswire.com\\\/media\\\/NWI2M2NmODEtNWNjYy00MjBkLWI3M2MtNTk0ZWIwNTVlMzIxLTEwMzc0NTQtMjAyNi0wOS0xNy1lbg==\\\/tiny\\\/AKAMPION.png\"},\"datePublished\":\"2026-09-17T08:03:08+00:00\",\"dateModified\":\"2026-09-17T08:03:08+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#webpage\"},\"articleSection\":\"GlobeNewswire\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewswire\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"position\":2,\"name\":\"GlobeNewswire\",\"item\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#listItem\",\"name\":\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \\u20181ST-104\\u2019\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#listItem\",\"position\":3,\"name\":\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \\u20181ST-104\\u2019\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewswire\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\",\"name\":\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan\",\"description\":\"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/Pakistan-News.png\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#organizationLogo\",\"width\":191,\"height\":78,\"caption\":\"Pakistan-News\"},\"image\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/\",\"name\":\"Gias Ul Hassan\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#webpage\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/\",\"name\":\"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \\u20181ST-104\\u2019\",\"description\":\"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\\u2019s Type 2 LRRK2\\\/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 \\u2014 1ST Biotherapeutics, Inc. (\\u201c1STBIO\\u201d) and SK Biopharmaceuticals Co., Ltd. (\\u201cSKBP\\u201d) today announced that they have entered into an exclusive\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml-eu.globenewswire.com\\\/media\\\/NWI2M2NmODEtNWNjYy00MjBkLWI3M2MtNTk0ZWIwNTVlMzIxLTEwMzc0NTQtMjAyNi0wOS0xNy1lbg==\\\/tiny\\\/AKAMPION.png\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#mainImage\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\\\/#mainImage\"},\"datePublished\":\"2026-09-17T08:03:08+00:00\",\"dateModified\":\"2026-09-17T08:03:08+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#website\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/\",\"name\":\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan\",\"description\":\"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \u20181ST-104\u2019","description":"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive","canonical_url":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#blogposting","name":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \u20181ST-104\u2019","headline":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019","author":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"publisher":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/ml-eu.globenewswire.com\/media\/NWI2M2NmODEtNWNjYy00MjBkLWI3M2MtNTk0ZWIwNTVlMzIxLTEwMzc0NTQtMjAyNi0wOS0xNy1lbg==\/tiny\/AKAMPION.png"},"datePublished":"2026-09-17T08:03:08+00:00","dateModified":"2026-09-17T08:03:08+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#webpage"},"isPartOf":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#webpage"},"articleSection":"GlobeNewswire"},{"@type":"BreadcrumbList","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news#listItem","position":1,"name":"Home","item":"https:\/\/pakistaninewspaperlist.com\/news","nextItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewswire"}},{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","position":2,"name":"GlobeNewswire","item":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/","nextItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#listItem","name":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019"},"previousItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#listItem","position":3,"name":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019","previousItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewswire"}}]},{"@type":"Organization","@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization","name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan","description":"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","url":"https:\/\/pakistaninewspaperlist.com\/news\/","logo":{"@type":"ImageObject","url":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#organizationLogo","width":191,"height":78,"caption":"Pakistan-News"},"image":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author","url":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/","name":"Gias Ul Hassan"},{"@type":"WebPage","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#webpage","url":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/","name":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \u20181ST-104\u2019","description":"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#website"},"breadcrumb":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#breadcrumblist"},"author":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"creator":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/ml-eu.globenewswire.com\/media\/NWI2M2NmODEtNWNjYy00MjBkLWI3M2MtNTk0ZWIwNTVlMzIxLTEwMzc0NTQtMjAyNi0wOS0xNy1lbg==\/tiny\/AKAMPION.png","@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#mainImage"},"primaryImageOfPage":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/#mainImage"},"datePublished":"2026-09-17T08:03:08+00:00","dateModified":"2026-09-17T08:03:08+00:00"},{"@type":"WebSite","@id":"https:\/\/pakistaninewspaperlist.com\/news\/#website","url":"https:\/\/pakistaninewspaperlist.com\/news\/","name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan","description":"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","inLanguage":"en-US","publisher":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization"}}]},"og:locale":"en_US","og:site_name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan - Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","og:type":"article","og:title":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \u20181ST-104\u2019","og:description":"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive","og:url":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/","og:image":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","og:image:secure_url":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","article:published_time":"2026-09-17T08:03:08+00:00","article:modified_time":"2026-09-17T08:03:08+00:00","twitter:card":"summary_large_image","twitter:title":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \u20181ST-104\u2019","twitter:description":"Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO\u2019s Type 2 LRRK2\/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 \u2014 1ST Biotherapeutics, Inc. (\u201c1STBIO\u201d) and SK Biopharmaceuticals Co., Ltd. (\u201cSKBP\u201d) today announced that they have entered into an exclusive","twitter:image":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png"},"aioseo_meta_data":[],"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/pakistaninewspaperlist.com\/news\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/\" title=\"GlobeNewswire\">GlobeNewswire<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate \u20181ST-104\u2019\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/pakistaninewspaperlist.com\/news"},{"label":"GlobeNewswire","link":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/"},{"label":"1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson&#039;s Disease Candidate \u20181ST-104\u2019","link":"https:\/\/pakistaninewspaperlist.com\/news\/1st-biotherapeutics-and-sk-biopharmaceuticals-announce-exclusive-global-license-agreement-for-parkinsons-disease-candidate-1st-104\/"}],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/113474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=113474"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/113474\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/113475"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=113474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=113474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=113474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}